Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

NEW HAVEN, Conn., March 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VIOND) today announced financial results for the fourth quarter and year-end of 2007.

The Company reported a net loss of $34.0 million, or $5.05 per share, for the year ended December 31, 2007, compared with a net loss of $25.3 million, or $3.83 per share, for 2006. Weighted-average common shares outstanding for the years ended December 31, 2007 and December 31, 2006 were 6.7 million and 6.6 million, respectively. The net loss increased in 2007 by $8.7 million over the previous year, primarily as a result of non-cash expenses including: (i) $5.1 million of interest expense related to Vion's convertible senior notes and (ii) $2.5 million of higher stock-based compensation expense. In addition, costs associated with clinical, regulatory and pre-commercialization activities for the Company's lead product candidate, Cloretazine(R) (VNP40101M) increased year-over-year.

The Company reported ending the year with $61.1 million in cash and cash equivalents.

Alan Kessman, Chief Executive Officer, commented, "Based on our current operating plan, we are funded through the third quarter of 2009. We continue to make progress on preparing a New Drug Application for our lead anticancer agent Cloretazine(R) (VNP40101M) for filing with the U.S. Food and Drug Administration in 2008."

A net loss of $8.2 million, or $1.18 per share, was reported for the fourth quarter of 2007, compared with a net loss of $6.1 million, or $0.92 per share, for the same period in 2006. Weighted-average common shares outstanding for the three months ended December 31, 2007 and 2006 were 6.9 million and 6.6 million, respectively.

On February 20, 2008, the Co
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ON (PRWEB) January 15, 2014 AudioNotch ... experimental new therapy for the treatment of tinnitus. Patients ... tinnitus frequency, and over a period of weeks to months, ... Sound Therapy in two forms: Notched Music and Notched White ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
(Date:1/14/2014)... 14, 2014 As pet owners drew up their lists of ... wrote: "Take better care of my furry companion." Nowadays there are ... top-brand carrying cases to take the little canine or feline darlings ... compelled to buy some pricey toys at the pet store. But ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX: NVN) announced today financial ... amounts, unless,specified otherwise, are in Canadian dollars. Nventa ... per share, for the,three months ended September 30, 2007, ... per share, for the same period in 2006. For ...
... Nov. 7 BioSpace, the leading biotech job,board ... 300 biotechnology,and pharmaceutical job seekers to the BioSpace ... The BioSpace Career Fair attracted a steady ... diagnostics career,candidates from around the Maryland biotechnology cluster ...
... of Reading, School of Pharmacy have developed an important new ... premature birth and prenatal mortality. The findings are published in ... ONE. , Dr Che Connon, a Research Councils UK Fellow ... powerful X-ray beam to examine tiny structures within the protective ...
Cached Biology Technology:Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 2Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 3Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results 4BioSpace Career Fair in Bethesda, Maryland Draws Hundreds of Industry Professionals 2Synchrotron radiation illuminates how babies' protective bubble bursts 2
(Date:4/17/2014)... news release is available in German . ... us to recognise objects; they also provide us with a ... run, turn around, fall or sit still in a car ... motion trace on our retinas. Seemingly without effort, our brain ... maintain a stable position and a steady gaze during our ...
(Date:4/17/2014)... eight years ago, Katia Silvera , a postdoctoral scholar ... on a field trip in a mountainous area in central ... seen before. , Unable to identify it, they contacted German ... out to be an unnamed species. So Carnevali recently named ... is the genus name, comprising about 40 species in the ...
(Date:4/17/2014)... in Europe, Asia and the United States are spreading ... impacting native honeybee populations at this time, according to ... including Nosema microsporidia and Varroa ... to these invasive pests, which suggests to us that ... and the United States currently are not necessary in ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... that conducts kidney tests and transmits data through a ... office visits by people with diabetes and others with ... was developed in the research lab of Aydogan Ozcan, ... UCLA Henry Samueli School of Engineering and Applied Science, ...
... that exposure to low to moderate amounts of arsenic ... about 120 parts per billion of arsenic in well ... damage comparable to decades of smoking tobacco. Smoking, especially ... is the first population-based study to clearly demonstrate significant ...
... Satellite pictures of Saharan dust clouds have been in the ... raised more questions., How much impact did the Saharan dust ... home-grown dust?, Chellam, a professor in the department of civil ... of Engineering, is searching for answers to those and other ...
Cached Biology News:UCLA researchers invent portable device for common kidney tests 2Study adds lung damage to harmful effects of arsenic 2Study adds lung damage to harmful effects of arsenic 3Study adds lung damage to harmful effects of arsenic 4Unraveling the mystery of Saharan dust migration 2